urothelial carcinoma

Open Access
Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
NOBUKI FURUBAYASHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, YUSHI FUJIMOTO, MOTONOBU NAKAMURA and TAKAHITO NEGISHI

Anticancer Research May 2025, 45 (5) 2185-2193; DOI: https://doi.org/10.21873/anticanres.17592
Open Access
Unusual Presentation of Advanced Urothelial Cancer in a Young Patient
DANIELA GUEVARA, NARA SHIN, ALEXANDRA BOIKO, IVAN VALIEV, AHMED G. ELSAEED, JUAN MIGUEL MOSQUERA, MAJD AL ASSAAD, JYOTHI MANOHAR, MICHAEL SIGOUROS, ALISA ZAICHIKOVA, VICTORIA FOMCHENKOVA, LEYSAN YUNUSOVA, SOFIA SMIRNOVA, OLIVIER ELEMENTO, DAVID NANUS and CORA N. STERNBERG

Anticancer Research February 2025, 45 (2) 613-618; DOI: https://doi.org/10.21873/anticanres.17448
Open Access
Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy
MICHELE DIONESE, DAVIDE BIMBATTI, FRANCESCO PIERANTONI, ELEONORA LAI, ELISA ERBETTA, NICOLÒ CAVASIN, SALIM JUBRAN, UMBERTO BASSO and MARCO MARUZZO

Anticancer Research October 2024, 44 (10) 4379-4386; DOI: https://doi.org/10.21873/anticanres.17267
Open Access
The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells In Vitro
DAVID ZEKAN, THOMAS HOGAN, BARBARA JACKSON, GARRETT JACKSON and STANLEY KANDZARI

Anticancer Research August 2024, 44 (8) 3243-3254; DOI: https://doi.org/10.21873/anticanres.17142
Open Access
Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, YOOHYUN SONG, KENICHI HARADA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO, MOTONOBU NAKAMURA and Uro-Oncology Group in Kyushu (UROKYU)

Anticancer Research August 2024, 44 (8) 3409-3417; DOI: https://doi.org/10.21873/anticanres.17161
Open Access
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research August 2024, 44 (8) 3419-3426; DOI: https://doi.org/10.21873/anticanres.17162
Open Access
Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, YOOHYUN SONG, KENICHI HARADA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO, MOTONOBU NAKAMURA and Uro-Oncology Group in Kyushu (UROKYU)

Anticancer Research July 2024, 44 (7) 3025-3032; DOI: https://doi.org/10.21873/anticanres.17115
You have access
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer
HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research May 2024, 44 (5) 1925-1930; DOI: https://doi.org/10.21873/anticanres.16994
You have access
Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma
WATARU FUKUOKAYA, KOHEI AKAZAWA and TAKAHIRO KIMURA

Anticancer Research May 2024, 44 (5) 2117-2123; DOI: https://doi.org/10.21873/anticanres.17017
You have access
Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model
RYO SATO, KYOHEI WATANABE, YUTO MATSUSHITA, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, ATSUSHI OTSUKA and HIDEAKI MIYAKE

Anticancer Research April 2024, 44 (4) 1417-1423; DOI: https://doi.org/10.21873/anticanres.16938

Main menu

User menu

Search

urothelial carcinoma

Pages